16:38 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

Zealand's hypoglycemia candidate meets in second Phase III

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said dasiglucagon (ZP4207) met the primary endpoint in a second Phase III trial to treat severe hypoglycemia in patients with Type I diabetes. The trial is evaluating a liquid formulation...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
20:31 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

Zealand starts second Phase III of dasiglucagon for severe hypoglycemia

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) began a second Phase III trial to evaluate dasiglucagon delivered in a rescue pen to treat severe hypoglycemia in 156 Type I diabetics. The primary endpoint of the double-blind, placebo-controlled...
20:25 , Aug 9, 2017 |  BC Extra  |  Financial News

Zealand lists on NASDAQ

Metabolic company Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) began trading on NASDAQ Wednesday after pricing a follow-on of ADSs underwritten by Morgan Stanley and Goldman Sachs. The company raised $78.2 million through the sale of 4.4...
20:11 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

Zealand begins Phase III of dasiglucagon in severe hypoglycemia

Zealand Pharma A/S (CSE:ZEAL) began a double-blind, international Phase III trial comparing repeated doses of 0.6 mg subcutaneous dasiglucagon in a rescue pen to GlucaGen for 15 weeks in 90 Type I diabetics with severe...
19:02 , Jul 7, 2017 |  BC Extra  |  Financial News

Zealand planning NASDAQ listing

Metabolic company Zealand Pharma A/S (CSE:ZEAL) filed to raise up to $86.3 million via a listing of ADSs on NASDAQ underwritten by Morgan Stanley and Goldman Sachs. Zealand's partner Sanofi (Euronext:SAN; NYSE:SNY) markets the company's...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Dasiglucagon in rescue pen: Phase II data

A double-blind, crossover, German Phase II trial in 58 Type I diabetics with severe hypoglycemia showed that all patients who received single doses of 0.3, 0.6 and 1 mg subcutaneous dasiglucagon or who received subcutaneous...
08:00 , Feb 15, 2016 |  BC Week In Review  |  Clinical News

ZP4207 in rescue pen: Phase II started

Zealand began a double-blind, crossover, German Phase II trial to compare single doses of 0.1, 0.3, 0.6 and 1 mg subcutaneous ZP4207 vs. 0.5 and 1 mg subcutaneous GlucaGen glucagon in about 56 Type I...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

ZP4207 in rescue pen: Phase I data

A German Phase I trial in 64 healthy volunteers and 20 Type I diabetics showed that single doses of 0.01-2 mg ZP4207 were well tolerated. Additionally, ZP4207 increased blood glucose levels after insulin-induced hypoglycemia and...